CalciMedica (NASDAQ: CALC) — Perfil da empresa, notícias e dados financeiros
CalciMedica develops critical care therapies targeting acute inflammatory diseases, focusing on CRAC channel inhibitors.
CalciMedica
CalciMedica (NASDAQ:CALC) focuses on developing critical care therapies for patients with acute and life-threatening inflammatory diseases. This biopharmaceutical company is especially concentrated on leveraging its expertise in calcium release-activated calcium (CRAC) channel inhibitors to treat conditions such as acute pancreatitis and other diseases where CRAC channels play a key role. CalciMedica aims to revolutionize the way acute inflammatory conditions are treated by advancing its leading compound through clinical trials and ultimately to the market, making a significant impact on patient care. The company, solely listed on NASDAQ, embodies a mission to address the unmet medical needs in critical care with innovative, effective treatments.
Resumo
Operações
Produtos e/ou serviços de CalciMedica
- Auxora, a CRAC channel inhibitor for treating acute pancreatitis and COVID-19 pneumonia.
- Development of novel CRAC channel inhibitors for autoimmune diseases and neuroinflammatory disorders.
- Research on CRAC channel modulation to address acute lung injury.
- Exploration of therapies for critical care conditions, including sepsis and acute kidney injury.
- Investigation into applications of CRAC channel inhibitors for cardiac ischemia-reperfusion injury.
- Study of potential treatments for inflammatory bowel disease leveraging CRAC channel inhibition.
equipe executiva do CalciMedica
- A. Rachel LehenyCEO & Director
- Eric W. RobertsChief Business Officer & Vice Chairman of the Board
- Sudarshan HebbarChief Medical Officer
- Michael J. DunnPresident & COO
- Anjana RaoCo-Founder and Scientific Advisor
- Patrick HoganCo-Founder and Scientific Advisor
- Stefan FeskeCo-Founder and Scientific Advisor
- Kenneth A. StaudermanCo-Founder & Chief Scientific Officer
- Stephen B. BardinChief Financial Officer
- John M. DunnGeneral Counsel
Principais indicadores financeiros
Resultados divulgados pela CalciMedica , em USD.
- Cap. de mercado
- 8,9 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -6.8
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -23,1 mi | -29,6 mi | |
| 0 | -24,2 mi | -13,7 mi | |
| 0 | -38,1 mi | -34,4 mi | |
| 0 | -14,2 mi | -7,8 mi |